As title indicates, amends GS 90-12.7(a) to change the definition of opioid antagonist from naloxone hydrochloride that is approved by the FDA for treatment of a drug overdoes to an opioid antagonist that is approved by the FDA for treatment of a drug overdose. Makes conforming changes to GS 90-113.27 by requiring that needle and hypodermic syringe exchange programs offer access to opioid antagonist (was, naloxone) kits that contain an opioid antagonist approved by FDA for the treatment of a drug overdose, or referrals to programs providing access to an opioid antagonist that is approved by the FDA for the treatment of a drug overdose. Makes additional conforming changes.
Bill Summaries: H35 EXPAND DEFINITION OF OPIOID ANTAGONIST.
Printer-friendly: Click to view
Tracking:
-
Bill H 35 (2023-2024)Summary date: Jan 30 2023 - View Summary